What targeted therapies are available for Cervical Cancer

Targeted Therapies for Cervical Cancer

Targeted therapies represent an important advancement in cervical cancer treatment, especially for advanced, recurrent, or metastatic disease. Unlike traditional chemotherapy that affects many cell types, targeted therapies work by attacking specific features (called "biomarkers") on cancer cells. Here's what you should know:

How Targeted Therapies Work

According to the NCCN Guidelines for Cervical Cancer, targeted therapies are most effective when your cancer has specific genetic or protein markers. Your oncologist will recommend testing for these biomarkers to determine which targeted therapies might work for your situation.

---

Key Targeted Therapy Options

HER2-Targeted Therapies

What is HER2? HER2 is a protein found on some cancer cells. Cervical cancers with HER2 amplification (overexpression) are associated with higher recurrence rates and worse prognosis, which is why testing is important.

Available options:

• Trastuzumab deruxtecan (Enhertu) - An antibody-drug conjugate (a targeted drug attached to chemotherapy) approved by the FDA for HER2-positive cervical cancer. According to NCCN Guidelines, this is recommended as a second-line or subsequent therapy option for patients with HER2-positive tumors (IHC 3+ or 2+).

• Neratinib - Recommended for patients with HER2-mutant cervical cancer (a specific type of HER2 change). Based on the SUMMIT trial results, this is listed as a useful option for certain circumstances.

Testing recommendation: The NCCN Panel recommends HER2 immunohistochemistry (IHC) testing with reflex to HER2 FISH for equivocal results for advanced, metastatic, or recurrent cervical carcinoma.

---

Immunotherapy (Checkpoint Inhibitors)

These drugs help your immune system recognize and attack cancer cells. They're particularly important for recurrent or metastatic cervical cancer.

Available options:

• Pembrolizumab (Keytruda) - FDA-approved for cervical cancer with PD-L1 expression (CPS ≥1). According to NCCN Guidelines, this is a Category 1 (preferred) first-line option when combined with chemotherapy and/or bevacizumab for persistent, recurrent, or metastatic disease.

• Nivolumab (Opdivo) - Another checkpoint inhibitor showing efficacy in pretreated patients. The CheckMate-358 trial demonstrated a 26.3% response rate in advanced cervical cancer patients.

• Cemiplimab (Libtayo) - FDA-approved for recurrent cervical cancer, showing survival benefits in the EMPOWER-Cervical trial.

Testing recommendation: The NCCN Panel recommends PD-L1 testing by FDA-approved assay for patients with recurrent, progressive, or metastatic disease to guide treatment selection.

---

Rare Mutation-Targeted Therapies

For patients with specific genetic mutations, these tumor-agnostic therapies (meaning they work across cancer types) may be options:

NTRK Gene Fusion:

• Larotrectinib, entrectinib, and repotrectinib - These TRK inhibitors are recommended as second-line or subsequent therapy for NTRK-positive tumors (Category 2A per NCCN Guidelines).

RET Gene Fusion:

• Selpercatinib - FDA-approved for RET fusion-positive solid tumors. NCCN recommends this as a second-line/subsequent therapy option for RET-positive cervical cancer.

High Microsatellite Instability (MSI-H) or Mismatch Repair Deficiency (dMMR):

• Pembrolizumab - Can be effective for tumors with these features, independent of PD-L1 status.

---

Comprehensive Molecular Testing

According to NCCN Guidelines, the Panel recommends comprehensive molecular profiling using an FDA-approved assay or validated CLIA-certified laboratory for patients with metastatic or recurrent disease. This testing should include:

• HER2 status
• Mismatch repair (MMR)/microsatellite instability (MSI)
• Tumor mutational burden (TMB)
• NTRK mutations
• RET mutations

This comprehensive approach helps identify all possible targeted therapy options for your specific cancer.

---

Important Questions to Ask Your Oncologist

1. "Should my tumor be tested for biomarkers like PD-L1, HER2, NTRK, RET, and MSI/MMR?"

2. "Based on my biomarker results, which targeted therapies are options for me?"

3. "What are the benefits and side effects of each targeted therapy option?"

4. "Are there clinical trials available for targeted therapies I might be eligible for?"

5. "How will we monitor whether the targeted therapy is working?"

6. "What happens if the cancer becomes resistant to the first targeted therapy?"

---

Key Takeaway

Targeted therapies offer personalized treatment options based on your cancer's specific characteristics. Testing for biomarkers is critical to identify which therapies might work best for you. These options are particularly valuable for advanced or recurrent disease where traditional chemotherapy alone may not be sufficient.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

---

Sources cited:

• NCCN Guidelines for Cervical Cancer (Version 1.2026)
• FDA approvals and clinical trial data referenced in NCCN Guidelines